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Accelerated cellular senescence (ACS) is an emerging concept that implicates sustained, telomere-independent cell cycle arrest 
of neoplastic cells in response to chemotherapeutic agents, ionizing radiation, oxidative stress, or the presence of selective onco-
genic stimuli. Recent evidence suggests that a subset of tumor cells induced in a state of reversible ACS can escape cell cycle arrest 
and resume proliferation accounting for cancer progression. The purpose of this review is to describe our current understanding 
of ACS including signaling pathways of senescence escape, role of senescence biomarkers, and rationale for senescence-based 
therapy. This article is part of a Special Issue entitled “Apoptosis: Four Decades Later”.
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INTRODUCTION
Malignant solid tumors treated with chemotherapy 
and radiation typically exhibit disappointingly low re-
sponse rates. The majority of advanced tumors are 
limited to only partial responses and delayed cancer 
progression is observed despite continued therapy. 
Conventional cancer therapeutics have been recog-
nized to activate DNA damage signaling pathways that 
lead to apoptotic cell death. There is increasing evi-
dence that apoptosis may not be the dominant pathway 
whereby tumor cells lose their proliferative capacity 
in response to cancer treatment. Cellular senescence, 
as first described by Hayflick [1] in 1961 while studying 
normal human fibroblasts, is defined as a quiescent 
state of proliferative arrest despite preservation of cell 
viability and maintained metabolic activity [2]. Replica-
tive senescence has long been described for normal 
tissues grown under culture conditions and “aging”-
associated physiological arrest has been shown to limit 
the replicative lifespan of normal cells in response 
to gradual erosion of the telomere. Senescent cells can 
be identified by characteristic morphologic features in-
cluding enlarged and flattened cell shape with increased 
cytoplasmic granularity, nuclear polyploidy, and expres-
sion of the senescence marker, β-galactosidase (SA-β-
gal) [3, 4]. Cellular senescence has also been observed 
in neoplastic cells and has been increasingly recognized 
as a tumor suppression mechanism accounting for the 
proliferative arrest observed in many benign tumors [5]. 
Malignant tumors are characterized by their ability to by-
pass replicative senescence, but can be induced into 
a state of cell cycle arrest following cancer treatment 
termed acce lerated cellular senescence (ACS). Mount-
ing evidence suggests that ACS is a prominent solid 
tumor response to therapy [6, 7] which most reasonably 
accounts for early treatment responses by prolonging 
cell cycle arrest. However, subsets of senescent cancer 
cells are capable of escaping senescence and resum-
ing cell division leading to eventual tumor progression. 
The purpose of this overview is to describe our current 
understanding of ACS including signaling pathways 
of senescence escape, role of senescence biomar kers, 
and rationale for senescence-based therapy.
SENESCENCE RESPONSE TO CANCER 
THERAPY AND REVERSIBILITY
Reversibility of ACS fundamentally distinguishes 
senescence from programmed cell death (apoptosis 
and autophagy) and mitotic catastrophe as cells enter 
a sustained period of replicative arrest with the possi-
bility of cell cycle reentry. It follows that senescent cells 
are destined for either terminal cell death or eventual 
bypass of senescence (escape) to resume replica-
tion. Cell fate during ACS appears to be an important 
determinant of cancer treatment efficacy. Rare cancer 
cells following recovery from chemotherapy can es-
cape senescence and resume proliferation which has 
been estimated to occur at a frequency of 1 × 106 cells 
[8]. Escape from therapy-induced senescence has 
been consistently demonstrated, but the mechanisms 
regulating cell cycle reentry of senescent cell remains 
poorly understood.
In contrast, much is known about oncogene-
induced senescence which has been proposed 
as a tumor suppressor mechanism in premalignant 
states such as dysplastic melanocytic nevus [9, 10], 
neurofibroma [11], and Barrett’s esophagus [12]. 
In these premalignant cells, oncogenic stress appears 
to trigger premature senescence through components 
of the DNA damage response (DDR), the MEK/ERK, 
and the p14ARF pathways, whose signals converge 
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onto the p53/p21 or the p16/pRB replicative senes-
cence pathway [13, 14]. Progression of premalignant 
lesions into invasive cancer necessitates additional 
loss of tumor suppressor functions within these path-
ways. Therapy-induced ACS invoked in malignant 
tumors following cancer treatment, therefore, almost 
always takes place in the absence of p53, p21, p16, 
and pRB function in epithelial solid tumors. These 
findings may explain the decade long observation that 
mutational status of these tumor suppressor genes 
often fail to reliably predict clinical outcome [15–17].
Despite these differences between oncogene- and 
therapy-induced ACS in premalignant and malignant 
tumors, components of ataxia telangiectasia-mutated/-
Rad3 (ATM/ATR) and the DDR pathways also transduce 
DNA damage signals in response to chemotherapy 
[18–20]. Chk1 and Chk2 serine/threonine kinases and 
their downstream effectors, mediate signals caused 
by stalled replication forks, single and double stranded 
breaks, and telomere dysfunction resulting in activation 
of G1-, S- and G2/M-cell cycle checkpoints (Fig. 1) [18, 
21]. The senescence program appears to be triggered 
by protracted checkpoint activation leading to terminal 
cell cycle arrest and eventual cell death by delayed 
apoptosis or autophagy. An emerging body of evidence 
now suggests that a subpopulation of therapy-induced 
senescent cells can reverse or escape ACS and evade 
cell death [22–24]. The viability of these escape cells 
must be maintained during senescence and they must 
acquire mechanisms to overcome barriers of cell cycle 
reentry. Therefore, a clear understanding of molecu-
lar determinants of senescence reversibility is crucial 
to reinforce terminal senescence response in cancer 
therapeutics. The following is a brief review of key com-
ponents of therapy-induced senescence reversibility 
in the absence of p53 and p16 pathway functions (Fig. 1).
Cdk1
Activated cyclin B1/Cdk1 complex is the master 
switch for cell entry into mitosis. In response to DNA 
damage, Chk1/2 phosphorylates and inactivates 
Cdc25C phosphatase, which prevents dephosphory-
lation of cyclin B1/Cdk1 complex and is typically con-
fined to an inactive state by inhibitory phosphorylation 
of Cdk1 at 14T and 15Y during G2 [25]. This negative 
regulatory event is currently believed to be mediated 
by the Wee1/Mik1 family of protein kinases [26, 27]. 
Wee1 itself is also regulated by phosphorylation and 
can be phosphorylated by Chk1 in vitro. Addition-
ally, the Kip/Cip family of cyclin-dependent kinase 
inhibitors p21 and p27 can directly bind the cyclin B1/
Cdk1 complex and down-regulate Cdk1 kinase activity. 
The consequence of DNA damage for a vast majority 
of cancer cells with defective p53 function is a rapid 
cell cycle arrest at G2. Recent evidence now suggests 
that down-regulation of Cdk1 protein level is required 
to maintain cell cycle dormancy during senescence 
(Fig. 1). This biphasic Cdk1 regulation has been ob-
served in a variety of systems, including senescent 
fibroblasts [28] and several human cancer cell lines [8, 
29–32]. Down-regulation of Cdk1 may be necessary 
in senescence as its activation has been implicated 
during apoptosis of YAC lymphoma cells in response 
to a lymphocyte granule protease [33] and inactivation 
of Cdk1 in this instance was shown to block apoptosis. 
A number of cellular proteins also appear to target Cdk1, 
which in turn suppresses senescence. These include 
the JNK activation kinase MKK7 and NIMA-related 
mitotic kinase Nek6 [29, 30]. Embryonic fibroblasts 
derived from MKK7–/– homozygous knockout mice 
spontaneously undergo G2/M cell cycle arrest and pre-
mature senescence in conjunction with down-regulation 
of Cdk1. Nek6 was recently found to prevent reduction 
of cyclin B1/Cdk1 following chemotherapy treatment 
in H1299 and EJ carcinoma cells and thereby suppress 
the senescence response.
Fig. 1. Pathways of Therapy-induced ACS in p53-null cancer 
cells. The signals induced by therapy related DNA damage are 
transduced by the components of the DDR pathway involving ATM/
ATR, Chk1/Chk2, and Cdc25C (not depicted) resulting in inacti-
vation of the cyclin B1-Cdk1 complex and rapid cell cycle arrest 
in G2. As cells enter ACS, further down-regulation of Cdk1 level 
reinforces the dormancy. Based on marker studies [63], the 
overwhelming majority of senescent cells transition from a state 
of potential cell cycle reversibility to irreversibility. The reversible 
cells, however, maintain a relatively high Cdk1 expression and 
kinase activity which is essential for senescence viability and 
escape. Survivin, whose function depends on Cdk1 phosphory-
lation, inhibits apoptosis. p21 also blocks apoptosis but through 
a mechanism that unrelated to Cdk1 kinase activity. Another Cip/
Kip protein p27 also bind to Cdk1 and directly inhibit Cdk1 kinase 
and Cdk1 mediated function in senescence. Reversible senescent 
cells reenter cell cycle while the irreversible senescent cells even-
tually die by delayed apoptosis, autophagy or other mechanisms
Despite the requirement of low Cdk1 levels in ACS, 
Cdk1 activity is required to maintain viability of senescent 
cells during therapy-induced senescence. Work in our 
laboratory has demonstrated that abrupt disruption 
of Cdk1 kinase activity by pharmacological inhibitors 
or through genetic modulation predictably elicits apop-
tosis of camptothecin-induced senescent H1299 cells 
[8]. On the other hand, aberrantly high Cdk1 levels 
are typically found in senescence escape cells and 
ectopic expression of a constitutively activated version 
of Cdk1 in senescent cells facilitates escape. Altogether, 
these findings suggest that a subpopulation of senes-
cent cells that manages to escape cell cycle arrest may 
be inherently different in their biological makeup, perhaps 
by over-expressing anti-apoptosis proteins that protect 
cells from the pro-apoptotic effects of high Cdk1 activ-
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ity. One such protein is the inhibitor of apoptotic protein 
(IAP) survivin, which is further discussed below. Notably 
Cdk1 has been shown to promote immortalization of nor-
mal human foreskin fibroblasts [34]. When Cdk1, or cy-
clin A, is transduced into these cells in primary culture, 
spontaneous immortalized colonies emerge. 
Interestingly these immortalized cells have consis-
tently lost alleles of p53 or p21, raising the possibility that 
Cdk1 level may represent a critical senescence barrier 
in the p53-defective background of most cancer cells.
Survivin
Survivin, a 16.5 kDal nuclear protein, is the small-
est member of the human IAP family [35, 36]. Survivin 
is expressed in a cell cycle-dependent manner with 
a marked rise during mitosis and functions to regulate 
cell division [37–39]. The protein is phosphorylated 
at the threonine-34 (T34) residue by Cdk1, which stabi-
lizes survivin and appears necessary for interaction with 
the mitotic spindle and inhibition of caspase-9 apop-
totic activity [39]. In HeLa cells, the microtubule in-
hibitor, taxol, activates a putative survival checkpoint 
through the up-regulation of Cdc2/Cdk1 kinase activity 
which leads to the phosphorylation and accumulation 
of survivin. Suppression of survivin phosphorylation 
by the Cdc2/Cdk1 kinase inhibitor, flavopiridol, was 
shown to enhance adriamycin-induced apoptosis [40].
We have found that survivin is consistently up-regulat-
ed in cancer cells that have managed to escape therapy-
induced senescence [41] and survivin appears to account 
for Cdk1-mediated survival function. Virally transduced 
survivin expression in senescent cells, for example, both 
reduces apoptosis and promotes senescence escape. 
A short peptide derived from the Cdk1 phosphorylation 
domain on survivin has been shown to efficiently block 
survivin phosphorylation and induces rapid apoptosis 
in senescence escape cells. Consistent with our find-
ings, F14512 is a novel epipodophylootoxin derivative that 
preferentially induces ACS while promoting both survivin 
and phosphor-survivin expression in HBL melanoma 
cells [42]. The knockdown of survivin using SiRNA con-
verts the predominately F14512 senescence response 
to apoptosis. More recently, survivin over-expression 
has been shown to reverse spontaneous senescence 
in stem cell marker ABCG-negative IRG37 melanoma 
cells [43]. Survivin expression occurs with high frequen-
cies in many types of human cancers including 85–96% 
of lung cancer specimens [44], 100% of colon adeno-
carcinoma [45], 71% of prostate adenocarcinomas [46], 
80% of glioblastomas [47] and nearly 100% of laryngeal 
carcinomas [48]. Survivin expression has been associ-
ated with unfavorable clinical prognosis in cancers of the 
breast, esophagus, stomach, pancreas, and colon [44, 
49, 50]; and has been shown to correlate with therapy 
resistance in a variety of clinical settings. For example, 
in one analysis of 60 advanced ovarian cancers treated 
with Taxol, complete pathological response was pro-
duced in 100% of survivin-negative tumors but only 43% 
of survivin-expressing tumors [51]. These findings sup-
port speculation that survivin is an important determinant 
of cell cycle reversibility for cells in ACS.
Cyclin-dependent Kinase Inhibitors: p16, 
p21 and p27
CDKIs p16, p21 and p27 interact with multiple 
cyclin and cyclin-dependent complexes during cell 
cycle regulation and therapy-induced DDR, and likely 
provide cytoprotective functions [52, 53]. p16 binds 
to CDK4/6 and prevents phosphorylation of Rb. The 
p16/RB axis has been linked to both physiological 
and ACS, where a complex of genetic and epigenetic 
controls regulate p16 expression [54]. p21 and p27 are 
well known for their roles as regulators of the G1 cell 
cycle progression [55]. p21 mediates an anti-apop-
totic effect through its known interaction with stress 
activated protein kinases, apoptosis signal-regulating 
kinase 1 in the cytoplasm [56], procaspase-3 in the 
mitochondria [57], or by its release from Cdk2 in the 
nucleus [58]. During mitosis, the presence of p27 has 
been proposed to prevent premature entry into S-
phase during the mitotic cell cycle, whereas p21 ap-
pears to suppress Cdk-1 mediated apoptosis leading 
to tolerance of genotoxic stress [59].
It is clear that the presence or the absence of func-
tional p53, single or combination of CDKIs and the type 
of stressor can each dramatically alter the function 
of intact CDKI during senescence. Using single cell 
analysis to characterize senescent cells derived from 
human ataxia telangiectasia and Li-Fraumeni syn-
drome, the expression of either p16 or p21 was shown 
to correlate with senescence induced by ionizing 
radiation depending on the presence or the absence 
of p53 [60]. We have demonstrated in the p53-null, 
p16-silenced H1299 cells, both p21 and p27 appear 
to interact with the cyclin B1/Cdk1 complex; however, 
only p27 modulates the Cdk1 kinase activity following 
DNA damage (Fig. 1). While the knockdown of p27 sup-
presses ACS, knockdown of p21 results in massive 
apoptosis. This suggests that both of these Kip/Cip 
family members may serve distinct pro- and anti-
apoptotic functions during senescence. Therefore, 
the determinants of therapy-induced ACS in cancer 
cells may be highly variable dependent upon distinct 
senescence pathways.
SENESCENCE MARKERS OF TREATMENT 
RESPONSE
Standard chemotherapy regimens have been 
shown to exert their effects by forcing cancer cells 
to enter a state of dormancy and absent proliferation 
despite the preservation of metabolic activity. These 
senescent cancer cells are phenotypically characte-
rized by features of enlarged and flattened shape with 
increased cytoplasmic granularity, nuclear polyploidy, 
and expression of pH-restricted senescence-associ-
ated b-galactosidase (SA-b-gal). Evidence of in vivo 
ACS is accumulating and has been reported for se-
veral types of cancer. A retrospective study of archival 
tumor samples obtained from patients with breast 
carcinoma following cyclophosphamide, doxorubicin, 
and 5-FU therapy found SA-b-gal expression in 41% 
of patients treated with prior chemotherapy com-
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Fig. 2. ACS in human cancers following treatment. a: Hemotoxylin-Eosin, in situ SA-β-galactosidase and anti-Cdk1 IHC staining 
of surgery specimens derived from 2 patients with intermediate stage non-small cell lung carcinoma. One patient received neoad-
juvant chemotherapy (CTX) prior to surgery (top panel) and the other underwent surgery alone (lower). Tumor or adjacent normal 
lung specimens were analyzed. Senescence response is clearly demonstrated in the tumor sample of the patient who received 
chemotherapy but not in the adjacent normal lung or tumor specimen from the patient who did not receive chemotherapy. b: In situ 
SA-b-galactosidse staining of freshly frozen specimens derived from 2 patients with rectal cancer, one of whom received neoadjuvant 
chemotherapy (CTX) and radiation (XRT). Evidence of therapy-induced ACS is clearly shown
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pared to only 10% of specimens from patients who 
underwent surgery alone [61]. SA-b-gal expression 
correlated with high expression levels of p16 but in-
versely with the p53 expression indicative of p53 muta-
tions. Interestingly 20% of tumor samples among the 
p53 overexpressing samples were positive for ACS 
which suggests that while p53-dependent mecha-
nisms promote ACS, p53-independent mechanisms 
likely mediate ACS response to therapy. In trans-
genic murine models using Bcl-2 over-expressing 
lymphomas, tumor response to cyclophosphamide 
was shown to correlate with senescence response 
which was attenuated by the accumulation of either 
p53 or p16 mutations [62].
Demonstration of senescence in human tumor sam-
ples raises the possibility that senescence mar kers may 
have prognostic value for cancer treatment. Our group 
has reported in vivo evidence of chemotherapy-induced 
senescence in patients treated for advanced lung and 
colorectal cancer [8, 63] (Fig. 2). We conducted a clini-
copathological study to determine whether senescence 
response correlates with clinical outcome in patients 
with locally advanced non-small cell lung cancer (stages 
II and IIIA, AJCC 6th edition) who underwent neoadjuvant 
(preoperative) therapy prior to surgery. A total of eigh-
teen lung cancer patients were included with a me-
dian follow-up time of 27 months. ACS was detected 
in 78% (14/18) of patients according to tumor-specific 
SA-b-gal expression relative to adjacent normal lung 
tissues (Fig. 2 a). Viable tumor cells were confirmed 
on patho logy in all 14 SA-b-gal expressing specimens. 
A Kaplan — Meier survival analysis was performed 
to compare the outcome of these two subgroups (Fig. 3) 
and demonstrated decreased overall survival in patients 
with tumors that over-expressing SA-b-gal compared 
to patients without detectable senescence marker 
expression. Despite the limited number of patients 
in this small pilot study, it nonetheless reached statisti-
cal significance with p=0.04 on a two-tailed Kaplan — 
Meier analysis. Within the limitations of this preliminary 
observation, we propose that senescence response 
may predict disease recurrence and adverse treatment 
outcome. Most recently the negative prognostic effect 
of senescence response was shown in patients who 
underwent neoadjuvant chemotherapy for malignant 
pleural mesothelioma [64]. This study demonstrated 
that elevated expression of plasminogen activator in-
hibitor-1 (PAI-1), a surrogate marker for senescence 
response, was also associated with statistically inferior 
survival. These findings collectively suggest that ACS 
leading to terminal growth arrest is a physiological 
mechanism of DDR during cancer therapy and could 
be used to predict clinical outcome.
Previous studies have demonstrated that non-can-
cerous cells in replicative senescence are less prone 
to adenoviral infection as a result of reduced surface 
coxsackie-adenovirus receptor (CAR) expression [65, 
66]. CAR has also been shown to mediate adenoviral-
mediated gene transfer in a variety of human malignan-
cies including glioma, melanoma, lung and pancreatic 
cancer [67–69]. We observed that tumor cells treated 
with chemotherapeutic agents and induced to a state 
of ACS could be differentiated by both their susceptibil-
ity to adenoviral transfection and levels of surface CAR 
expression [63]. Using both surface CAR expression and 
marker adenovirus transduction as a surrogate determi-
nant for CAR, morphologically identical senescent tumor 
cell populations can be functionally distinguished by their 
ability to escape senescence. The subpopulation of se-
nescent cells with increased surface CAR expression, 
retain the ability to escape cell cycle arrest. Conversely, 
low CAR expressing senescent cells appear confined 
to a prolonged senescent state destined for eventual cell 
death. The ability to characterize transitional senescent 
states based upon adenoviral marker transduction ef-
ficiency and CAR expression provides unique insights 
into the biological properties of ACS.
Fig. 3. Senescence response as a prognosticator of treatment 
outcome in 18 patients with intermediate stage (IIB, and IIIA) non-
small cell lung cancer. These patients were enrolled in a institutional 
review board-approved protocol and received either chemotherapy 
or combined chemotherapy and radiation per recommendation 
of the multidisciplinary tumor board. At the time of surgery, tumor and 
adjacent normal lung specimens were collected and assayed for SA-
b-gal (see example in Fig. 2). Patients were followed for a median time 
of 34 months. Evidence of ACS was detected in 78% (14/18) based 
on the SA-b-gal expression of the tumor relative to that of adjacent 
normal lung tissues. Viable tumor cells were found on pathology in all 
14 SA-b-gal expressing specimens. Conversely, no viable tumor cells 
could be identified in the four cases which showed no evidence of se-
nescence response. A two tailed Kaplan — Meier survival analysis was 
performed to compare the outcome of these 2 subgroups and shows 
a significantly decreased overall survival in patients with tumors that 
over-expressed SA-b-gal than patients whose surgery specimens 
showed no detectable senescence marker expression (p=0.04)
Tumor samples obtained from rectal cancer pa-
tients treated with preoperative chemoradiation prior 
to surgical resection were immunostained with CAR 
antibody and compared to patients undergoing resec-
tion without prior treatment [63]. Decreased CAR stain-
ing was observed in tumors treated with preoperative 
chemoradiotherapy compared to untreated tumors. 
Meanwhile CAR expression appeared unchanged 
in the surrounding normal colonic mucosa suggesting 
that down-regulation of CAR expression in response 
to preoperative chemoradiation is a tumor-specific 
property. This provocative finding in rectal cancer 
patients suggests that CAR expression and adenoviral 
transduction efficiency may be convenient methodolo-
gies to study fundamental regulatory events in ACS and 
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further studies are warranted to examine the role of CAR 
as a candidate therapy-induced senescence biomarker.
Additional senescence markers have been proposed 
with limited or unproven clinical efficacy. IGFBP-3, a serum 
protein shown to induce growth arrest and apoptosis, 
has been used as a treatment response marker in animal 
models of prostate cancer and found to be upregulated 
in senescent prostate cancer cells [70, 71]. However, clini-
cal studies of IGF markers in cancer patients have shown 
limited effectiveness with disappointingly low sensitivity 
and specificity [72]. Other markers, such as the senes-
cence associated heterochromatin foci [73], heterochro-
matin protein 1g [74,75], and PAI-1 [64, 74], have been 
applied in both in vitro and in vivo situations. Each of these 
suffers from the lacking of systematic stu dies to assess 
their value in clinical situations. There remains an important 
need to identify robust prognostic markers of senescence 
which can be studied in prospective clinical trials.
FUTURE DEVELOPMENT OF SENESCENCE-
BASED CANCER THERAPY
Manipulating senescence response in tumors pre-
sents a novel approach to cancer treatment. For the 
majority of solid tumors, induction chemotherapy alone 
results in modest disease response rates of 20–40% 
and rarely results in complete tumor eradication [76]. 
Initial tumor responses with reduction in tumor size and 
volume are often followed by tumor growth and pro-
gression despite continued therapy. It is assumed that 
senescent tumor cells induced by anticancer agents 
are able to escape cell cycle arrest and resume prolif-
eration accounting for cancer progression. Therapeutic 
strategies to enforce therapy-induced senescence and 
bypass escape pathways have been proposed. These 
include pharmacologic agents such as CDK inhibitors 
intended to block reversible senescence. One of the first 
pharmacologic CDK inhibitors to enter clinical trials is fla-
vopiridol which has been shown to have antitumor effects 
in a wide range of solid tumors including renal, colon, 
and prostate cancer patients [77, 78]. Recent evidence 
in dose-escalation and dose-sequencing trials suggests 
that flavopiridol can potentiate the effects of standard 
chemotherapy agents [78]. It remains to be established 
whether CDK inhibitors can be effectively used with che-
motherapy to modulate senescence response.
Statins (3-hydroxy-3-methylglutaryl-coenzyme 
A reductase inhibitors) commonly used for the treat-
ment of dyslipidemia have also been shown to decrease 
farnesylation and geranylgeranylation of several proteins 
essential for cellular proliferation and survival [79]. Statin 
agents have been reported to demonstrate a broad 
spectrum of anti-tumor activities and shown to modulate 
chemotherapeutic effects in vitro [80]. For example, 
Atorvastatin and lovastatin was shown to potentiate 
the effect of chemotherapeutic agents in lung cancer 
cell lines [81]. Statins therefore have been explored 
as potential preventive and therapeutic agents for hu-
man cancers [82, 83]. A retrospective study of from the 
VA Health Care System found evidence that statin use 
reduces the risk of lung cancer in the Veterans popula-
tion [84]. This study showed that statin use for greater 
than 6 months was associated with an unexpected 55% 
risk reduction independent of race, age and tobacco 
use (p<0.01). Currently, only a few clinical trials have 
been performed to study statin treatment for human 
cancers. In a study of hepatocellular carcinoma patients, 
Pravastatin and 5-FU conferred a statistically significant 
survival advantage when compared with 5-FU alone 
[85]. The effect of statin was examined in patients with 
colorectal cancer treated with neoadjuvant chemoradio-
therapy. Lovastatin used concurrently with neoadjuvant 
chemoradiation resulted in a higher complete patho-
logical response rate compared to those who did not 
receive a statin drug (30% vs. 17%; p=0.10). Interest-
ingly, statins have been shown to down-regulate several 
key targets of the Cdk1 pathway, including Cdk1 itself, 
cyclin B1, survivin, and up-regulate CDKI p27. We have 
demonstrated that statin drugs can block escape and 
reinforce senescence in colorectal cell lines previously 
exposed to chemotherapy (unpublished data). Para-
doxically, statins administered alongside chemotherapy 
were found to promote senescence escape suggesting 
that statins may exhibit both agonistic and antagonistic 
effects on therapy-induced senescence. These early 
observations suggest that statin use in cancer therapy 
may require stringent scrutiny both in terms of dose 
intensity and administration schedule in relationship 
to chemotherapy to establish clinical efficacy.
CONCLUSION
Cellular senescence plays an important role along-
side apoptosis in determining tumor responses to the 
stresses imposed by cancer treatment. There is accu-
mulating evidence that conventional therapies including 
chemotherapy and radiation induce senescence-like 
phenotypes classified as ACS. Further studies of the 
mechanisms that influence transitional states in ACS 
are crucial for a better understanding of the signaling 
pathways that ultimately lead to either cancer death 
or progression. The identification and validation of ro-
bust senescence markers is needed to detect in vivo 
senescence and could be combined with tumor imaging 
modalities such as PET to provide a real-time measure 
of tumor response that would enable treatment modi-
fications and lead to more personalized cancer thera-
pies. Lastly, clinical trials incorporating pharmacologic 
agents designed to target senescence pathways are 
encouraged to investigate whether manipulation of se-
nescence response can improve the clinical efficacy 
of anti-cancer agents and improve patient survival.
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